Find Ritlecitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1792180-81-4, Pf-06651600, Ritlecitinib, 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, 2oye00pc25, Pf-06651600 free base
Molecular Formula
C15H19N5O
Molecular Weight
285.34  g/mol
InChI Key
CBRJPFGIXUFMTM-WDEREUQCSA-N
FDA UNII
2OYE00PC25

Ritlecitinib
Ritlecitinib is an orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
1 2D Structure

Ritlecitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
2.1.2 InChI
InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
2.1.3 InChI Key
CBRJPFGIXUFMTM-WDEREUQCSA-N
2.1.4 Canonical SMILES
CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
2.1.5 Isomeric SMILES
C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
2.2 Other Identifiers
2.2.1 UNII
2OYE00PC25
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(5-((7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

2. Pf-06651600

2.3.2 Depositor-Supplied Synonyms

1. 1792180-81-4

2. Pf-06651600

3. Ritlecitinib

4. 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

5. 2oye00pc25

6. Pf-06651600 Free Base

7. 1-[(2s,5r)-2-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

8. Pf06651600

9. Pf 06651600

10. Ritlecitinib?

11. 2-propen-1-one, 1-((2s,5r)-2-methyl-5-(7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-1-piperidinyl)-

12. Ritlecitinib [inn]

13. Unii-2oye00pc25

14. Ritlecitinib [who-dd]

15. Gtpl9559

16. Chembl4085457

17. Schembl16764638

18. Bcp24778

19. Ex-a2613

20. Example 5 [wo2015083028]

21. Zinc526061581

22. Ccg-267324

23. Db14924

24. Compound 11 [pmid: 28139931]

25. Ac-35550

26. Bp168506

27. Hy-100754

28. Cs-0020243

29. S8538

30. C91239

31. Pf06651600;pf 06651600

2.4 Create Date
2016-02-23
3 Chemical and Physical Properties
Molecular Weight 285.34 g/mol
Molecular Formula C15H19N5O
XLogP32.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass285.15896025 g/mol
Monoisotopic Mass285.15896025 g/mol
Topological Polar Surface Area73.9 Ų
Heavy Atom Count21
Formal Charge0
Complexity402
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of alopecia areata


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

03

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jinan Tantu Chemicals

04

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IMCAS World Congress
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

06

Shanghai Hope Chem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IMCAS World Congress
Not Confirmed
arrow

07

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IMCAS World Congress
Not Confirmed
arrow

08

Micro Labs Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IMCAS World Congress
Not Confirmed
arrow

Micro Labs Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IMCAS World Congress
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Hebi Xinhe Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IMCAS World Congress
Not Confirmed
arrow

10

Zhejiang Tianyu Pharmaceutical Co....

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IMCAS World Congress
Not Confirmed
arrow

Zhejiang Tianyu Pharmaceutical Co....

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IMCAS World Congress
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ritlecitinib Tosylate Manufacturers

A Ritlecitinib Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ritlecitinib Tosylate, including repackagers and relabelers. The FDA regulates Ritlecitinib Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ritlecitinib Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ritlecitinib Tosylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ritlecitinib Tosylate Suppliers

A Ritlecitinib Tosylate supplier is an individual or a company that provides Ritlecitinib Tosylate active pharmaceutical ingredient (API) or Ritlecitinib Tosylate finished formulations upon request. The Ritlecitinib Tosylate suppliers may include Ritlecitinib Tosylate API manufacturers, exporters, distributors and traders.

click here to find a list of Ritlecitinib Tosylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ritlecitinib Tosylate GMP

Ritlecitinib Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ritlecitinib Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ritlecitinib Tosylate GMP manufacturer or Ritlecitinib Tosylate GMP API supplier for your needs.

Ritlecitinib Tosylate CoA

A Ritlecitinib Tosylate CoA (Certificate of Analysis) is a formal document that attests to Ritlecitinib Tosylate's compliance with Ritlecitinib Tosylate specifications and serves as a tool for batch-level quality control.

Ritlecitinib Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Ritlecitinib Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ritlecitinib Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Ritlecitinib Tosylate EP), Ritlecitinib Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ritlecitinib Tosylate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty